As biopharmaceuticals continue to dominate the market, the need for greater shelf life and protein stability has increased. For many biological products lyophilization is a necessity and the technology is constantly advancing.
One of the main challenges in pharmaceutical lyophilization, continues to be the scale - up and the implementation of QbD protocols for the optimization of cycles. Several companies are researching and developing ways to facilitate commercial bulk lyophilization of vaccines, protein and cells while also reducing costs.
Lyophilization USA will gather scientific leaders and drug manufacturers to discuss the latest cutting edge developments in freeze drying, as well as solutions to on-going industry challenges.
Key Topics Addressed:
One of the main challenges in pharmaceutical lyophilization, continues to be the scale - up and the implementation of QbD protocols for the optimization of cycles. Several companies are researching and developing ways to facilitate commercial bulk lyophilization of vaccines, protein and cells while also reducing costs.
Lyophilization USA will gather scientific leaders and drug manufacturers to discuss the latest cutting edge developments in freeze drying, as well as solutions to on-going industry challenges.
Key Topics Addressed:
- The impact of controlled nucleation on product quality and the technology being used for controlled ice nucleation.
- Examining the development and scale up of a freeze-drying cycle for biotherapeutics.
- Highlighting the approaches to effective holistic packaging and innovative design.
- Future developments in continuous manufacturing.
- Lokesh Kumar, Associated Scientist, Genentech
- Charlie Tang, Associate Director, Formulation Development, Regeneron Pharmaceuticals
- Guido Schmitz, Global Head of Packaging & Technology Innovation, Bayer Consumer Care
- Perceval Sondag, Principal Statistician, Arlenda
- Eric Munson, Professor, Pharmaceutical Sciences, University of Kentucky
- Kelly Forney Stevens, Drug Product Development, GSK Vaccines
- Melissa Lash, Scientist, Large Molecule Drug Development, Johnson & Johnson
